NasdaqCM:EXAS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. More Details


Snowflake Analysis

Slightly overvalued with limited growth.


Similar Companies

Share Price & News

How has Exact Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EXAS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

2.4%

EXAS

-1.2%

US Biotechs

0.4%

US Market


1 Year Return

18.1%

EXAS

32.5%

US Biotechs

17.8%

US Market

Return vs Industry: EXAS underperformed the US Biotechs industry which returned 32.5% over the past year.

Return vs Market: EXAS matched the US Market which returned 17.8% over the past year.


Shareholder returns

EXASIndustryMarket
7 Day2.4%-1.2%0.4%
30 Day12.3%2.3%6.1%
90 Day15.7%-2.6%8.9%
1 Year18.1%18.1%34.7%32.5%20.5%17.8%
3 Year119.0%119.0%20.0%14.0%42.3%32.9%
5 Year1,004.7%1,004.7%11.5%3.4%84.2%63.4%

Price Volatility Vs. Market

How volatile is Exact Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Exact Sciences undervalued compared to its fair value and its price relative to the market?

43.6%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: EXAS ($109.7) is trading below our estimate of fair value ($194.47)

Significantly Below Fair Value: EXAS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: EXAS is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: EXAS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate EXAS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EXAS is overvalued based on its PB Ratio (6.6x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Exact Sciences forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?

79.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EXAS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: EXAS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: EXAS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: EXAS's revenue (27.9% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: EXAS's revenue (27.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: EXAS is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Exact Sciences performed over the past 5 years?

0.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EXAS is currently unprofitable.

Growing Profit Margin: EXAS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: EXAS is unprofitable, but has reduced losses over the past 5 years at a rate of 0.1% per year.

Accelerating Growth: Unable to compare EXAS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EXAS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.1%).


Return on Equity

High ROE: EXAS has a negative Return on Equity (-6.15%), as it is currently unprofitable.


Next Steps

Financial Health

How is Exact Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: EXAS's short term assets ($1.5B) exceed its short term liabilities ($222.3M).

Long Term Liabilities: EXAS's short term assets ($1.5B) do not cover its long term liabilities ($1.7B).


Debt to Equity History and Analysis

Debt Level: EXAS's debt to equity ratio (62.1%) is considered high.

Reducing Debt: EXAS's debt to equity ratio has increased from 0.9% to 62.1% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EXAS has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if EXAS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Exact Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate EXAS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EXAS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EXAS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EXAS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EXAS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure


CEO

Kevin Conroy (54 yo)

11.5yrs

Tenure

US$18,716,543

Compensation

Mr. Kevin T. Conroy serves as Director of Adaptive Biotechnologies Corporation since April 2019. Mr. Conroy has been the Chief Executive Officer and President at Exact Sciences Corporation since April 2, 2 ...


CEO Compensation Analysis

Compensation vs Market: Kevin's total compensation ($USD18.72M) is above average for companies of similar size in the US market ($USD11.16M).

Compensation vs Earnings: Kevin's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Kevin Conroy
Chairman of the Board11.5yrsUS$18.72m0.67%
$ 111.1m
Jeffrey Elliott
Chief Financial Officer3.92yrsUS$5.12m0.026%
$ 4.3m
Ana Hooker
Senior Vice President of Operations5.75yrsUS$3.95m0.14%
$ 22.9m
D. Coward
Chief Administrative Officer2.25yrsUS$5.07m0.036%
$ 6.0m
Jake Orville
Senior Vice President of Pipeline1.67yrsUS$4.06m0.0018%
$ 294.9k
G. Cole
General Manager of Precision Oncologyno dataUS$2.10m0.0068%
$ 1.1m
Gary Frings
Chief Information Officer5.75yrsno datano data
Scott Johnson
Chief Science Officer and Senior VP of Research & Development1.75yrsno data0.0083%
$ 1.4m
Megan Jones
Associate Manager of Investor Relationsno datano datano data
Tim Caprez
Chief Compliance Counsel & VP5.75yrsno datano data
Vic Parker
Head of Sales1.83yrsno datano data
Kristen Weiler
Vice President of Marketing1.83yrsno datano data

3.1yrs

Average Tenure

54yo

Average Age

Experienced Management: EXAS's management team is considered experienced (3.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Kevin Conroy
Chairman of the Board11.5yrsUS$18.72m0.67%
$ 111.1m
Andrew Slavitt
Director1.25yrsUS$780.00k0.0063%
$ 1.0m
Daniel Levangie
Independent Director10.25yrsUS$329.02k0.010%
$ 1.6m
Michael Wyzga
Independent Director5.67yrsUS$331.02k0.0076%
$ 1.3m
Katherine Zanotti
Independent Director11.5yrsUS$326.02k0.053%
$ 8.7m
Freda Lewis-Hall
Independent Director0.50yrno data0.0056%
$ 929.1k
Kathleen Sebelius
Independent Director1.58yrsUS$811.49k0.0074%
$ 1.2m
Thomas Carey
Independent Director7.5yrsUS$319.02k0.015%
$ 2.4m
Shacey Petrovic
Director0.25yrno data0.0042%
$ 696.8k
James Doyle
Lead Independent Directorno dataUS$347.52k0.022%
$ 3.6m
Pierre Jacquet
Independent Director1.25yrsUS$694.00k0.0061%
$ 1.0m

3.6yrs

Average Tenure

65yo

Average Age

Experienced Board: EXAS's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16%.


Top Shareholders

Company Information

Exact Sciences Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Exact Sciences Corporation
  • Ticker: EXAS
  • Exchange: NasdaqCM
  • Founded: 1995
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$16.473b
  • Shares outstanding: 150.17m
  • Website: https://www.exactsciences.com

Number of Employees


Location

  • Exact Sciences Corporation
  • 441 Charmany Drive
  • Madison
  • Wisconsin
  • 53719
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EXASNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 2001
EXKDB (Deutsche Boerse AG)YesCommon StockDEEURJan 2001

Biography

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to de ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/26 05:35
End of Day Share Price2020/10/23 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.